Pilatus Biosciences Announces First Patient Dosed in Phase 1 Trial of First-in-Class Metabolic Checkpoint Antibody PLT012 in Solid Tumors

First-in-human study underway evaluating anti-CD36 monoclonal antibody designed to restore metabolic fitness in exhausted T cells, reduce immunosuppressive cells, and enhance antitumor immunity

Excerpt from the Press Release:

DOVER, Del. & EPALINGES, Switzerland–(BUSINESS WIRE)–Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced the first patient has been dosed in its Phase 1 clinical trial evaluating PLT012, a first-in-class anti-CD36 monoclonal antibody for the treatment of advanced solid tumors. The first patient was treated at Next Oncology in Houston, Texas.

PLT012 recently received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration. The antibody target, CD36, is a key regulator of lipid uptake and metabolic adaptation within the tumor microenvironment (TME). By blocking CD36-mediated fatty acid uptake, PLT012 aims to invigorate innate and adaptive effector cells, reduce immunosuppressive cell populations, and elicit durable tumoricidal immune responses.

“Dosing our first patient is an important milestone for Pilatus and validates our work advancing a new immuno-metabolic approach to cancer therapy,” said Raven Lin, CEO and Co-Founder, Pilatus Biosciences. “Many solid tumors create a metabolically hostile microenvironment that drives immune exhaustion and resistance to existing therapies. PLT012 is designed to directly address this metabolic suppression, with the goal of restoring effective antitumor immunity for patients with limited treatment options.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release